Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03968419
Title This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)
Acronym CANOPY-N
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | FRA | ESP | DEU | CAN | BEL

Facility Status City State Zip Country Details
UCLA Oncology Hematology La Jolla California 92037 United States Details
University of Kansas Medical Center Neurology Dept. Kansas City Kansas 66160 United States Details
SUNY - Upstate Medical University Syracuse New York 13210 United States Details
Methodist Hospital / Methodist Cancer Center Houston Texas 77030 United States Details
Novartis Investigative Site Bruxelles 1000 Belgium Details
Novartis Investigative Site Montreal Quebec H2W 1T8 Canada Details
Novartis Investigative Site Montpellier cedex 5 Herault 34059 France Details
Novartis Investigative Site Bron 69677 France Details
Novartis Investigative Site Paris 75679 France Details
Novartis Investigative Site Bad Berka 99437 Germany Details
Novartis Investigative Site Giessen 35392 Germany Details
Novartis Investigative Site Halle (Saale) 06120 Germany Details
Novartis Investigative Site Koeln 51109 Germany Details
Novartis Investigative Site Thessaloniki 57001 Greece Details
Novartis Investigative Site Kashiwa Chiba 277 8577 Japan Details
Novartis Investigative Site Breda 4819 EV Netherlands Details
Novartis Investigative Site Hertogenbosch 5200 Netherlands Details
Novartis Investigative Site Maastricht 6229 HX Netherlands Details
Novartis Investigative Site Omsk 644013 Russian Federation Details
Novartis Investigative Site Saint Petersburg 197022 Russian Federation Details
Novartis Investigative Site St Petersburg 195271 Russian Federation Details
Novartis Investigative Site Jaen Andalucia 23007 Spain Details
Novartis Investigative Site Oviedo Asturias 33011 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Taipei 103616 Taiwan Details
Novartis Investigative Site Taipei 110 Taiwan Details
Novartis Investigative Site Izmir Turkey Details
Novartis Investigative Site Sakarya 54290 Turkey Details
Novartis Investigative Site Sihhiye / Ankara 06100 Turkey Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field